{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:12:49Z","timestamp":1791403969940,"version":"4.3.3"},"reference-count":52,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jiph.2020.06.016","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T03:09:10Z","timestamp":1592276950000},"page":"1210-1223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":196,"title":["In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7835-7972","authenticated-orcid":false,"given":"Yogesh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvijay","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2020.06.016_bib0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2020.06.016_bib0010","unstructured":"WHO coronavirus disease (COVID-19) dashboard. n.d. https:\/\/covid19.who.int\/. [Accessed 15 May 2020]."},{"key":"10.1016\/j.jiph.2020.06.016_bib0015","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"0","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2020.06.016_bib0020","series-title":"Gilead to end coronavirus drug trials, adding to access worry \u2014 researchers","year":"2020"},{"key":"10.1016\/j.jiph.2020.06.016_bib0025","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2020.06.016_bib0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jiph.2020.06.016_bib0035","article-title":"Coronavirus disease 2019 (COVID-19)","author":"CDC","year":"2020","journal-title":"Cent Dis Control Prev"},{"key":"10.1016\/j.jiph.2020.06.016_bib0040","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health \u2014 the latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiph.2020.06.016_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.jiph.2020.06.016_bib0050","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3390\/v2081803","article-title":"Coronavirus genomics and bioinformatics analysis","volume":"2","author":"Woo","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.jiph.2020.06.016_bib0055","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1128\/JVI.79.9.5288-5295.2005","article-title":"Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus","volume":"79","author":"Hussain","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jiph.2020.06.016_bib0060","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1074\/jbc.C300520200","article-title":"A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2","volume":"279","author":"Wong","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jiph.2020.06.016_bib0065","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J"},{"key":"10.1016\/j.jiph.2020.06.016_bib0070","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.stem.2013.04.003","article-title":"A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS","volume":"12","author":"Yang","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jiph.2020.06.016_bib0075","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jiph.2020.06.016_bib0080","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jiph.2020.06.016_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2014.88","article-title":"Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs","volume":"3","author":"Kouznetsova","year":"2014","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.jiph.2020.06.016_bib0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010286","article-title":"Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection","volume":"7","author":"He","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jiph.2020.06.016_bib0095","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","article-title":"A screen of FDA-approved drugs for inhibitors of zika virus infection","volume":"20","author":"Barrows","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jiph.2020.06.016_bib0100","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/CM9.0000000000000797","article-title":"Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model","volume":"133","author":"Fan","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jiph.2020.06.016_bib0105","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2020.06.016_bib0110","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jiph.2020.06.016_bib0115","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/molbev\/mst197","article-title":"MEGA6: molecular evolutionary genetics analysis version 6.0","volume":"30","author":"Tamura","year":"2013","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.jiph.2020.06.016_bib0120","unstructured":"PubChem. PubChem. n.d. https:\/\/pubchem.ncbi.nlm.nih.gov\/. [Accessed 15 May 2020]."},{"key":"10.1016\/j.jiph.2020.06.016_bib0125","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"10.1016\/j.jiph.2020.06.016_bib0130","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1021\/ci200227u","article-title":"LigPlot+: multiple ligand-protein interaction diagrams for drug discovery","volume":"51","author":"Laskowski","year":"2011","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.jiph.2020.06.016_bib0135","unstructured":"PyMOL | pymol.org. n.d. https:\/\/pymol.org\/2\/. [Accessed 15 May 2020]."},{"key":"10.1016\/j.jiph.2020.06.016_bib0140","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jcc.23899","article-title":"New ways to boost molecular dynamics simulations","volume":"36","author":"Krieger","year":"2015","journal-title":"J Comput Chem"},{"key":"10.1016\/j.jiph.2020.06.016_bib0145","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/prot.20251","article-title":"Making optimal use of empirical energy functions: force-field parameterization in crystal space","volume":"57","author":"Krieger","year":"2004","journal-title":"Proteins"},{"key":"10.1016\/j.jiph.2020.06.016_bib0150","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s12010-015-1784-y","article-title":"Receptor-guided de novo design of dengue envelope protein inhibitors","volume":"177","author":"Desai","year":"2015","journal-title":"Appl Biochem Biotechnol"},{"key":"10.1016\/j.jiph.2020.06.016_bib0155","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-5-72","article-title":"Coronavirus 3CLproproteinase cleavage sites: possible relevance to SARS virus pathology","volume":"5","author":"Kiemer","year":"2004","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jiph.2020.06.016_bib0160","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jiph.2020.06.016_bib0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225381","article-title":"Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: a European survey","volume":"14","author":"De Luca","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jiph.2020.06.016_bib0170","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/17512433.2018.1500897","article-title":"Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients","volume":"11","author":"Foolad","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jiph.2020.06.016_bib0175","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2020.06.016_bib0180","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jiph.2020.06.016_bib0185","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s40265-018-1005-4","article-title":"Dolutegravir\/rilpivirine: a review in HIV-1 infection","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jiph.2020.06.016_bib0190","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bbrc.2004.04.083","article-title":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus","volume":"318","author":"Yamamoto","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jiph.2020.06.016_bib0195","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jiph.2020.06.016_bib0200","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkaa120","article-title":"Comment on: dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study","author":"Del Puente","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2020.06.016_bib0205","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2165\/00003495-200363150-00009","article-title":"Tipranavir","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.jiph.2020.06.016_bib0210","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/15284336.2018.1459343","article-title":"Raltegravir versus lopinavir\/ritonavir for treatment of HIV-infected late-presenting pregnant women","volume":"19","author":"Brites","year":"2018","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jiph.2020.06.016_bib0215","unstructured":"WHO Director-General\u2019s remarks at the media briefing on 2019-nCoV on 11 February 2020. n.d. https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. [Accessed 15 May 2020]."},{"key":"10.1016\/j.jiph.2020.06.016_bib0220","doi-asserted-by":"crossref","first-page":"9241","DOI":"10.1073\/pnas.2004999117","article-title":"Phylogenetic network analysis of SARS-CoV-2 genomes","volume":"117","author":"Forster","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jiph.2020.06.016_bib0225","article-title":"Coronavirus outbreak: top coronavirus drugs and vaccines in development","year":"2020","journal-title":"Clin Trials Arena"},{"key":"10.1016\/j.jiph.2020.06.016_bib0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jiph.2020.06.016_bib0235","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbrc.2020.02.071","article-title":"Structure analysis of the receptor binding of 2019-nCoV","volume":"525","author":"Chen","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jiph.2020.06.016_bib0240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2005.07.003","article-title":"Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir","volume":"68","author":"Doyon","year":"2005","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jiph.2020.06.016_bib0245","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/00002030-200009080-00009","article-title":"Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples","volume":"14","author":"Larder","year":"2000","journal-title":"AIDS Lond Engl"},{"key":"10.1016\/j.jiph.2020.06.016_bib0250","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2020.06.016_bib0255","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiph.2020.06.016_bib0260","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034120305268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034120305268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:08:05Z","timestamp":1761750485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034120305268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1876034120305268"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2020.06.016","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2020.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}